Looking into the future of CAR-T therapy: cardiac fibrosis, infections & autoimmune diseases
Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy, gives an overview of the session on new chimeric antigen receptor T-cell (CAR-T) indications that took place at this year’s EBMT-EHA CAR T-cell Meeting. To begin with, using animal models, Prof. Epstein provided a proof of principle for the development of CAR-Ts for the treatment of cardiac fibrosis. Subsequently, Prof. Mackensen demonstrated that CD19-targeted CAR-Ts induced rapid clinical remission and efficient B-cell depletion, with no notable adverse effects in refractory systemic lupus erythematosus (SLE). Prof. Protzer then shared a promising new therapeutic approach using bispecific T-cell engagers (BiTEs) to treat chronic hepatitis B infection and chronic hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). Finally, Dr Scott gave a presentation on engineering T-cells to modulate adverse immune responses and suppress immunogenic disorders, autoimmunity, and allergy. Altogether, these findings reveal the huge potential of CAR-T therapies in many applications beyond hematological malignancies. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
https://www.vjhemonc.com/video/tfqskbgfkk0-looking-into-the-future-of-car-t-therapy-cardiac-fibrosis-infections-autoimmune-diseases/
ارسال به دوستان